Psychotic illnesses demand timely detection, phase-specific care, and coordinated pharmacologic and psychosocial strategies. Psychotic Disorders reviews diagnostic frameworks, differential diagnosis, and trajectories from prodrome through first-episode and multi-episode phases. We examine positive, negative, and cognitive symptom clusters; comorbid substance use; and medical contributors such as autoimmune, metabolic, or neurodegenerative conditions. The session emphasizes shared decision-making, adverse-effect mitigation, and functional recovery—education, work, relationships—not just symptom reduction. You’ll learn how to balance efficacy with tolerability, when to add long-acting injectables, and how to integrate CBT-p, family work, and supported employment. We’ll also cover metabolic monitoring, cardiometabolic risk reduction, and strategies for suicidality and aggression risk. With real-world data and early-intervention models, teams can shorten DUP, reduce relapse, and improve quality of life. See how Psychotic Disorders, insights from psychosis conference, and adjacent concepts like schizophrenia treatment guidelines translate evidence into compassionate, equitable care.